The Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Biosimilars in Retinopathy of Prematurity.

AIM: Biosimilar anti-vascular endothelial growth factor agents are cheaper alternatives to current treatments, but their safety and efficacy are unknown. This review aims to evaluate the safety and efficacy of biosimilar anti-vascular endothelial gro…

Preview only. Read the full abstract at the source